What is Micro Interventional Devices?
Micro Interventional Devices (MID) is a specialized medical technology firm dedicated to the design, manufacturing, and commercialization of innovative catheter-based solutions. The company's core focus is the advancement of Transcatheter Cardiac Repair (TCR), specifically through its flagship MIA-T Percutaneous Tricuspid Annuloplasty System. By providing a less invasive alternative to traditional open-heart surgery, MID addresses critical gaps in current cardiac care, aiming to improve patient quality of life while simultaneously reducing operative times and enhancing procedural ease for surgeons. The company operates at the intersection of high-stakes clinical research and scalable medical manufacturing, serving as a vital link in the modern healthcare supply chain.
How much funding has Micro Interventional Devices raised?
Micro Interventional Devices has raised a total of $24.3M across 6 funding rounds:
Private Equity
$250K
Debt
$100K
Series B
$3.5M
Series D
$20M
Debt
$150K
Debt
$262K
Private Equity (2012): $250K with participation from The Life Sciences Greenhouse of Central Pennsylvania
Debt (2012): $100K led by Ben Franklin Technology Partners of Northeastern Pennsylvania
Series B (2013): $3.5M supported by Battelle Ventures, LP and Originate Ventures
Series D (2019): $20M featuring OSCOR
Debt (2020): $150K backed by PPP
Debt (2021): $262K with participation from PPP
Key Investors in Micro Interventional Devices
Battelle Ventures, LP
Battelle Ventures, L.P. and its affiliate, Innovation Valley Partners, manage significant capital to accelerate early-stage technology companies, often leveraging deep ties to national laboratories and university research centers.
Originate Ventures
An early-stage venture capital firm based in Pennsylvania that provides both financial backing and operational guidance to emerging companies, focusing on fostering growth within the regional entrepreneurial ecosystem.
The Life Sciences Greenhouse of Central Pennsylvania
An evergreen venture fund dedicated to strengthening the life sciences sector by providing early-stage capital and scientific support to companies involved in drug discovery, diagnostics, and healthcare IT.
What's next for Micro Interventional Devices?
With the recent influx of capital, Micro Interventional Devices is well-positioned to accelerate its commercialization efforts and expand the reach of its Transcatheter Cardiac Repair technologies. The strategic focus will likely shift toward scaling manufacturing capabilities to meet anticipated demand and deepening clinical evidence to support broader adoption among healthcare networks. As the company matures, the emphasis will remain on maintaining its competitive edge in the structural heart disease market, potentially exploring new indications for its existing technology platform. The firm's ability to leverage its established investor network—ranging from regional venture funds to strategic industry partners—will be instrumental in navigating the next phase of its growth, ensuring that its innovative solutions reach the patients who need them most while delivering sustained value to stakeholders.
See full Micro Interventional Devices company page
